KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Neogenomics (NEO) Shares Issued (2016 - 2026)

Neogenomics filings provide 17 years of Shares Issued readings, the most recent being -$338000.0 for Q1 2026.

  • On a quarterly basis, Shares Issued fell 135.62% to -$338000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$325000.0, a 106.8% decrease, with the full-year FY2025 number at $962000.0, down 79.29% from a year prior.
  • Shares Issued hit -$338000.0 in Q1 2026 for Neogenomics, down from $431000.0 in the prior quarter.
  • In the past five years, Shares Issued ranged from a high of $6.4 million in Q1 2022 to a low of -$1.2 million in Q2 2025.
  • Median Shares Issued over the past 5 years was $1.2 million (2024), compared with a mean of $1.3 million.
  • Biggest five-year swings in Shares Issued: skyrocketed 2013.98% in 2024 and later tumbled 160.17% in 2025.
  • Neogenomics' Shares Issued stood at $1.9 million in 2022, then crashed by 31.28% to $1.3 million in 2023, then plummeted by 46.08% to $687000.0 in 2024, then plummeted by 37.26% to $431000.0 in 2025, then crashed by 178.42% to -$338000.0 in 2026.
  • The last three reported values for Shares Issued were -$338000.0 (Q1 2026), $431000.0 (Q4 2025), and $765000.0 (Q3 2025) per Business Quant data.